Synaptogenix 将来の成長

Future 基準チェック /06

Synaptogenix の収益は、年間 32.9% 減少すると予測されています。EPS は、年間増加すると予測されています8%。

主要情報

-32.9%

収益成長率

8.0%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Jul 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

NasdaqCM:SNPX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-21	N/A	N/A	1
12/31/2025	N/A	-13	N/A	N/A	1
12/31/2024	N/A	-8	N/A	N/A	1
9/30/2024	N/A	-9	-5	-5	N/A
6/30/2024	N/A	-3	-5	-5	N/A
3/31/2024	N/A	-12	-5	-5	N/A
12/31/2023	N/A	-14	-5	-5	N/A
9/30/2023	N/A	-8	-7	-7	N/A
6/30/2023	N/A	-11	-8	-8	N/A
3/31/2023	N/A	-4	-9	-9	N/A
12/31/2022	N/A	-6	-11	-11	N/A
9/30/2022	N/A	-14	-10	-10	N/A
6/30/2022	N/A	-14	-9	-9	N/A
3/31/2022	N/A	-13	-9	-9	N/A
12/31/2021	N/A	-13	-9	-9	N/A
9/30/2021	N/A	-14	-8	-8	N/A
6/30/2021	N/A	-15	-10	-10	N/A
3/31/2021	N/A	-16	-10	-10	N/A
12/31/2020	N/A	-15	-8	-8	N/A
9/30/2020	N/A	-12	-8	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SNPX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SNPX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SNPX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SNPXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: SNPX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SNPXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Synaptogenix 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Synaptogenix, Inc., Annual General Meeting, Dec 06, 2024

Insufficient new directors

Synaptogenix, Inc. announced that it has received $3.207 million in funding

Synaptogenix, Inc. announced a financing transaction

New major risk - Revenue and earnings growth

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix, Inc. (NasdaqCM:SNPX) acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.

New major risk - Share price stability

Synaptogenix, Inc., Annual General Meeting, Dec 20, 2023

New major risk - Shareholder dilution

New minor risk - Share price stability

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix, Inc. announced that it has received $15 million in funding

Synaptogenix, Inc. announced that it expects to receive $15 million in funding

We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth

Synaptogenix, Inc., Annual General Meeting, Oct 11, 2022

Synaptogenix, Inc. Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Synaptogenix, Inc. announced that it has received $12.477342 million in funding

President recently bought US$83k worth of stock

Synaptogenix, Inc. announced that it expects to receive $12.499998 million in funding

Synaptogenix: The Next Big Thing In Alzheimer's

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update

Synaptogenix provides update on phase 2b Alzheimer's disease trial

We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate

Synaptogenix, Inc. announced that it has received $14.0033 million in funding

Synaptogenix Announces Licensing Agreement with Stanford University; and Supply Agreement with Bryologyx, Inc

Synaptogenix announced that it expects to receive $14 million in funding

Synaptogenix Inc Announces CEO Changes

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘